Inflammation levels in type 2 diabetes mellitus patients with mild cognitive impairment: Assessment followed by amelioration via dapagliflozin therapy

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications Pub Date : 2025-03-30 DOI:10.1016/j.jdiacomp.2025.109017

Wei Zhang , Chunping Sun , Yating Huang , Meng Zhang , Ao Xu , Chen Wang , Fang Lv , Tianrong Pan

{"title":"Inflammation levels in type 2 diabetes mellitus patients with mild cognitive impairment: Assessment followed by amelioration via dapagliflozin therapy","authors":"Wei Zhang , Chunping Sun , Yating Huang , Meng Zhang , Ao Xu , Chen Wang , Fang Lv , Tianrong Pan","doi":"10.1016/j.jdiacomp.2025.109017","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>To investigate systemic inflammation and the effect of dapagliflozin treatment in (type 2 diabetes mellitus) T2DM patients with mild cognitive impairment (MCI).</div></div><div><h3>Methods</h3><div>Between January and December 2023, 200 participants were recruited from the Department of Endocrinology of Hefei First People's Hospital. Baseline data collected included medical history, fasting blood glucose, HbA1c, liver and kidney function, lipid profiles, IL-1β, TNF-α, sVCAM-1 level, and the urinary albumin-creatinine ratio (uACR). Based on their Montreal Cognitive Assessment Scale (MoCA) scores, these participants were categorized into two groups: 127 in the MCI group and 73 in the non-MCI group. MCI group received dapagliflozin (10 mg daily) alongside standard treatment.</div></div><div><h3>Results</h3><div>The MCI group showed higher age, height, weight, BMI, HbA1c, FBG, disease duration, carotid plaques, stenosis rates, and elevated IL-1β, TNF-α, and sVCAM-1. MoCA scores were significantly lower in the MCI group. Correlation analysis showed a negative correlation of MoCA scores with IL-1β, TNF-α, sVCAM-1, plaques, stenosis, FBG, and HbA1c, and a positive correlation with height. Binary logistic regression identified age, BMI, IL-1β, sVCAM-1, and FBG as predictors of cognitive impairment in T2DM. Dapagliflozin treatment reduced BMI, HbA1c, inflammatory markers, and FBG, improving MoCA scores.</div></div><div><h3>Conclusion</h3><div>Dapagliflozin treatment may improve cognitive function by reducing inflammation.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 6","pages":"Article 109017"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of diabetes and its complications","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1056872725000704","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

To investigate systemic inflammation and the effect of dapagliflozin treatment in (type 2 diabetes mellitus) T2DM patients with mild cognitive impairment (MCI).

Methods

Between January and December 2023, 200 participants were recruited from the Department of Endocrinology of Hefei First People's Hospital. Baseline data collected included medical history, fasting blood glucose, HbA1c, liver and kidney function, lipid profiles, IL-1β, TNF-α, sVCAM-1 level, and the urinary albumin-creatinine ratio (uACR). Based on their Montreal Cognitive Assessment Scale (MoCA) scores, these participants were categorized into two groups: 127 in the MCI group and 73 in the non-MCI group. MCI group received dapagliflozin (10 mg daily) alongside standard treatment.

Results

The MCI group showed higher age, height, weight, BMI, HbA1c, FBG, disease duration, carotid plaques, stenosis rates, and elevated IL-1β, TNF-α, and sVCAM-1. MoCA scores were significantly lower in the MCI group. Correlation analysis showed a negative correlation of MoCA scores with IL-1β, TNF-α, sVCAM-1, plaques, stenosis, FBG, and HbA1c, and a positive correlation with height. Binary logistic regression identified age, BMI, IL-1β, sVCAM-1, and FBG as predictors of cognitive impairment in T2DM. Dapagliflozin treatment reduced BMI, HbA1c, inflammatory markers, and FBG, improving MoCA scores.

Conclusion

Dapagliflozin treatment may improve cognitive function by reducing inflammation.

查看原文本刊更多论文

伴有轻度认知障碍的2型糖尿病患者的炎症水平：评估后通过达格列净治疗改善

目的探讨达格列净治疗伴有轻度认知障碍（MCI）的2型糖尿病患者的全身性炎症及疗效。方法于2023年1 - 12月在合肥市第一人民医院内分泌科招募受试者200名。收集的基线数据包括病史、空腹血糖、HbA1c、肝肾功能、血脂、IL-1β、TNF-α、sVCAM-1水平和尿白蛋白-肌酐比值（uACR）。根据他们的蒙特利尔认知评估量表（MoCA）得分，这些参与者被分为两组：轻度认知障碍组127人，非轻度认知障碍组73人。MCI组在标准治疗的同时给予达格列净（每日10毫克）。结果MCI组患者年龄、身高、体重、BMI、HbA1c、FBG、病程、颈动脉斑块、狭窄率、IL-1β、TNF-α、sVCAM-1升高。MCI组的MoCA评分明显较低。相关性分析显示MoCA评分与IL-1β、TNF-α、sVCAM-1、斑块、狭窄、FBG、HbA1c呈负相关，与身高呈正相关。二元logistic回归发现年龄、BMI、IL-1β、sVCAM-1和FBG是T2DM认知功能障碍的预测因子。达格列净治疗可降低BMI、HbA1c、炎症标志物和FBG，改善MoCA评分。结论达格列净治疗可通过减轻炎症反应改善认知功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of diabetes and its complications 医学-内分泌学与代谢

CiteScore

5.90

自引率

3.30%

发文量

153

审稿时长

16 days

期刊介绍： Journal of Diabetes and Its Complications (JDC) is a journal for health care practitioners and researchers, that publishes original research about the pathogenesis, diagnosis and management of diabetes mellitus and its complications. JDC also publishes articles on physiological and molecular aspects of glucose homeostasis. The primary purpose of JDC is to act as a source of information usable by diabetes practitioners and researchers to increase their knowledge about mechanisms of diabetes and complications development, and promote better management of people with diabetes who are at risk for those complications. Manuscripts submitted to JDC can report any aspect of basic, translational or clinical research as well as epidemiology. Topics can range broadly from early prediabetes to late-stage complicated diabetes. Topics relevant to basic/translational reports include pancreatic islet dysfunction and insulin resistance, altered adipose tissue function in diabetes, altered neuronal control of glucose homeostasis and mechanisms of drug action. Topics relevant to diabetic complications include diabetic retinopathy, neuropathy and nephropathy; peripheral vascular disease and coronary heart disease; gastrointestinal disorders, renal failure and impotence; and hypertension and hyperlipidemia.